Washington, DC – August 12, 2022 – As leaders in the liver cancers community, Global Liver Institute (GLI) proudly supports President Biden’s selection of Monica Bertagnolli, MD, to be appointed as the Director of the National Cancer Institute (NCI).
Bertagnolli is the first woman to serve as chief of the Division of Surgical Oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute and is a professor of surgery at Harvard Medical School. She was recently elected to the National Academy of Medicine and served as the president of the American Society of Clinical Oncology.
“Global Liver Institute and our liver cancers team are grateful for President Biden appointing Dr. Monica Bertagnolli to be the first woman to serve as Director of the National Cancer Institute,” said Sarah Manes, Liver Cancers Program Director at GLI. “Dr. Bertagnolli’s esteemed and extensive clinical oncology experience, health policy work, and clinical trial expertise will continue to drive NCI to lead in the space of cancer research and innovation.”
Liver cancer presents a sizable burden as the sixth most common cancer and third leading cause of worldwide cancer death. Further, liver cancer is one of the few cancers that is on the rise – its incidence is expected to grow 137% by 2030. GLI remains committed to being an ally and driving focus on liver cancers advocacy specifically for hepatobiliary NCI SPORE grants and state-and-global-specific cancer consortiums. We look forward to collaborating with Dr. Monica Bertagnolli and the NCI on Cancer Moonshot initiatives as we persist in our efforts to drive policy, education, and awareness of liver disease and liver cancers by increasing screening, treatment, and prevention of one of the deadliest cancers in the world. We are also thankful to Dr. Douglas Lowy, MD, for serving as NCI’s acting director upon the departure of Ned Sharpless, MD.